# Chemical Development of Adafosbuvir

**Simon Wagschal**

*Chemical Process Research and Development, Janssen Pharmaceutica, Schaffhausen 8200, Switzerland.*

swagscha@its.jnj.com

Nucleoside analogues have emerged over the last decades as a well-established platform to treat cancer and viral infections. Phosphoramidate prodrug strategy was applied to 4'-fluoro-2'-C-methyluridine, a potent inhibitor of hepatitis C virus RNA-polymerase, leading to clinical candidate Adafosbuvir (AL-335). The route definition, the initial scale-up route, and the optimization towards large-scale production will be discussed.




**adafosbuvir**

[1] Cao, T.; Dyatkina, N.; Lemaire, S.; Prhavc, M.; Wagschal, S. *Complete Accounts of Integrated Drug Discovery and Development: Recent Examples from the Pharmaceutical Industry, Volume 4 (ACS Symposium Series), in press.*